PT-141 (bremelanotide) is a cyclic heptapeptide metabolite of Melanotan II that advanced through full Phase III clinical development and received FDA approval in June 2019 under the trade name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting agent approved for this indication.
During early clinical studies with MT-II at the University of Arizona, researchers observed unexpected pro-erectile effects in male volunteers, attributed to MC4R activation in spinal and supraspinal pathways. Subsequent structure-activity work identified the active cyclic metabolite of MT-II that retained MC4R activity with improved selectivity — this became PT-141.
The designation "PT-141" reflects its status as a research compound (peptide therapeutic 141) from Palatin Technologies, which acquired and developed the compound through clinical trials. Its structure — a cyclic heptapeptide with the pharmacophore sequence His-D-Phe-Arg-Trp — preserves the core melanocortin binding motif.
PT-141 acts primarily as an MC3R and MC4R agonist in the central nervous system. MC4R is widely expressed in the hypothalamus, limbic system, and spinal cord, where it modulates sexual arousal pathways independent of vascular mechanisms. This distinguishes bremelanotide's mechanism from PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle. PT-141 modulates desire and arousal centrally, making it potentially useful in populations where the primary deficit is motivational/psychological rather than vascular.
The RECONNECT trials (Simon et al., 2019; Portman et al., 2019) were two randomised, double-blind, placebo-controlled Phase III trials in premenopausal women with HSDD. Key outcomes:
Wessells et al. (1998, 2000) published Phase I/II data in men with erectile dysfunction showing statistically significant improvements in erectile function scores with MT-II and subsequently PT-141. Molinoff et al. and Safarinejad et al. extended this into larger Phase II trials confirming PT-141's pro-erectile activity in men. Palatin Technologies' development programme ultimately focused on the female HSDD indication due to competitive landscape considerations, but the male dataset remains published and informative for research purposes.
A key research insight from the PT-141 programme is the dissociation of central sexual motivation from peripheral vascular response. In animal models, MC4R antagonists block PT-141-induced sexual behaviour without affecting erectile response to direct penile stimulation — demonstrating that the compound's primary site of action is supraspinal. This model has become influential in understanding the neuroscience of sexual motivation and desire.
Research-grade PT-141 is used in neuropharmacological studies of MC4R signalling, sexual arousal circuitry, and melanocortin system interactions with dopamine and oxytocin pathways. The existence of approved clinical data provides important pharmacokinetic and safety context for in-vitro and preclinical study design.
